The claim in The Factum's 'Beijing's Pharma Death Grip' article that U.S. reliance on China for 25%+ of generic drug APIs and 41% of key starting materials creates an acute national security catastrophe overstates the risk and ignores diversification data. A 2023 GAO report found that while China supplies a notable share of certain precursors, the U.S. maintains strategic stockpiles and has accelerated domestic API production through the Defense Production Act, with over $100 million allocated since 2022. Indian manufacturers have captured increasing market share in finished generics, reducing single-point exposure, as documented in a 2024 FDA analysis of import data showing a 12% drop in direct Chinese API shipments for critical drugs between 2021-2023.